Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis

The use of TNF-alpha antagonists (infliximab, etanercept, adalimumab) has changed the course of many rheumatic diseases including rheumatoid arthritis (RA). Since their approval, some questions regarding their safety including infections have been observed. The aim of the study was to evaluate the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Benucci, M, Saviola, G, Baiardi, P, Manfredi, M, Sarzi Puttini, P, Atzeni, Fabiola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362853/
https://www.ncbi.nlm.nih.gov/pubmed/22655000
http://dx.doi.org/10.2174/1874312901206010033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362853/
https://www.ncbi.nlm.nih.gov/pubmed/22655000
http://dx.doi.org/10.2174/1874312901206010033

Ejemplares similares